Adicet Bio to Present at the American College of Rheumatology (ACR) Convergence 2024

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced acceptance of an oral presentation at the upcoming American College of Rheumatology (ACR) Convergence 2024 meeting, taking place November 14-19, 2024, in Washington, D.C.

Details of the oral presentation are as follows:

Title: ADI-001: An Allogeneic CD20-targeted γδ CAR T Cell Therapy with Potential for Improved Tissue Homing in Autoimmune Indications

Session Name: Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases II

Abstract Number: 1866169

Presenting Author: Monica Moreno, Ph.D.

Date and Time: November 19, 2024; 12:00 p.m. – 12:15 p.m. ET

About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  216.48
+3.44 (1.61%)
AAPL  262.24
+9.95 (3.94%)
AMD  240.56
+7.48 (3.21%)
BAC  52.04
+0.76 (1.48%)
GOOG  257.02
+3.23 (1.27%)
META  732.17
+15.26 (2.13%)
MSFT  516.79
+3.21 (0.63%)
NVDA  182.64
-0.58 (-0.32%)
ORCL  277.18
-14.13 (-4.85%)
TSLA  447.43
+8.12 (1.85%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.